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Extended spectrum b-lactamases (ESBL) are increasing rapidly worldwide. E. coli producing CTX-M type
ESBLs are the most common clinically encountered. The majority of E. coli ESBL infections are represented
by urinary tract infections, but they can also cause severe infections, for example, in the blood stream and
central nervous system. Since E. coli is a common colonizer of the normal gut microbiota, increasing
prevalence of ESBL-producing strains is particularly worrisome. Once disseminated in the community,
containment of this resistance type will be challenging. The driver of ESBL-producing Enterobacteriaceae
(EPE) is debated. Some suggest that the ESBL genes were introduced to particularly successful bacterial
clones. Others imply that very successful plasmids drive the rapid dissemination. More research and
epidemiological studies of strain types, plasmids and mobile genetic elements are needed for these questions to
be answered. In order to combat, or at least slow down, the worrisome trend of increasing numbers of EPE
more knowledge is also needed on persistence of EPE in carriers as well as better understanding of how
antibiotic treatment and other risk factors affect persistence and further dissemination. This review aims at
giving an overview of this global problem from a Nordic perspective.
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E
xtended spectrum b-lactamases (ESBLs) are en-
zymes produced by bacteria that degrade b-lactam
antibiotics with extended spectrum (such as third-
generation cephalosporins) (1). b-Lactams are exten-
sively used for the treatment of common infections,
for example, pneumonia and urinary tract infections
(UTI), as well as for severe and life threatening infections
such as bloodstream infections (BSI). b-Lactams are
also frequently used as prophylaxis treatment before
surgery.
Different nomenclatures have been proposed and de-
bated for b-lactamases which includes several hundreds
of enzymes (http://www.lahey.org/studies/webt.asp). Also
what to include in the ESBL definition is debated. In this
review, ESBLA as defined by Giske et al. will be used
(2). The Giske et al. definition divides ESBL enzymes in
three main groups; ESBLA, ESBLM and ESBLCARBA.
ESBLA includes the most frequently found CTX-M
enzymes as well as SHV and TEM enzymes that are
horizontally transferrable and degraded by clavulanic
acid. ESBLM are miscellaneous ESBLs where acquired
AmpC represent the most common type. ESBLCARBA are
enzymes conferring carbapenemase activity, such as me-
tallo b-lactamases and KPC (2).
The CTX-Ms were first discovered in the 1980s and
since 1995 they havespreadto all continents. The numbers
have since increased tremendously. The blaCTX-M genes
are divided into five phylogroups; CTX-M-1, CTX-M-2,
CTX-M-8,CTX-M-9andCTX-M-25(3,4).TheCTX-M-
1 phylogroup includes blaCTX-M-15 which is the most
dominant is found globally.
Enterobacteriaceae is the main bacterial family asso-
ciated to ESBL production, of which E. coli and K.
pneumoniae are most important.
Enterobacteriaceae are of clinical importance causing
infections in the central nervous system, lower respiratory
tract, bloodstream, gastrointestinal and urinary tract, but
are also common colonizers of the gastrointestinal tract
(GIT).
E. coli is the main causative agent of community-
acquired UTI (5). Women are more affected than men
due to anatomical differences.
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immunocompromised humans, and BSI. They are the
second most common cause of UTI.
K. pneumoniae are to a larger extent acquired in
hospital environments than in the community, for
example, in patients with urinary catheters or immuno-
compromised patients (6).
As the ESBL-carrier rate in the population increases
and nosocomial transmission becomes more common, the
risk of being infected increases. ESBL-producing Entero-
bacteriaceae (EPE) often displays multidrug-resistant
phenotypes further limiting the therapeutic options. Co-
resistance with fluoroquinolones, aminoglycosides and
trimethoprim are often found (7) which are common em-
pirical treatment options for severely ill patients resulting
in increased morbidity and mortality.
ESBLs also constitute a burden on health care systems
conferring prolonged hospital stay. de Kraker and co-
workers describe BSIs in Europe caused by E. coli isolates
resistant to extended spectrum cephalosporins. They esti-
mate the cost to  2,700 excess deaths and 18.1 million
EUR, represented by  120,000 excess days of hospital
stay (8).
Patients with severe infections are highly dependent on
receiving adequate treatment early in the course of
infection for a benign outcome. Many times the diag-
nostic procedures available are too slow and empirical
treatment necessary. Knowledge of the local epidemiol-
ogy is therefore very important. For a patient with BSI
caused by resistant bacteria, such as an ESBL-producer,
administration of an ineffective antibiotic can be lethal.
Changing to an effective regimen after treatment failure
might be too late (9). Peralta and coworkers studied the
rate of adequate empirical treatment in BSIs caused by
Enterobacteriaceae in 19 Spanish hospitals during 4
years. They found the empirical treatment to be inade-
quate in 48.8% of the cases. Twenty-four of the 387
patients included in the study died during the first 3 days
of inadequate therapy (10).
National and global epidemiology is also important
since it provides ways to detect emerging clones or new
types of resistant bacteria. A wider perspective can bring
valuable information to the practitioners treating patients
associated to other parts of the country or the world.
Governmental institutions and agencies play an impor-
tant role gathering data through different surveillance
tools.
Epidemiology of CTX-M-genes
Different ESBL genotypes have different substrate speci-
ficities for the many b-lactam antibiotics (11), also
between CTX-M enzymes. As mentioned blaCTX-Ms are
found all over the world and blaCTX-M-15 is the most
dominating genotype (12). However, local variations
occur. In the Nordic countries, the distribution of
genotypes is homogenous. In Sweden, 5060% of
ESBL-producing E. coli harbor blaCTX-M-15 followed
by blaCTX-M-14 f o u n di n1 0 15% (7). In Norway and
Denmark, about 50% and 20% of the genotypes are
blaCTX-M-15 and blaCTX-M-14 respectively (13, 14). The
ESBL epidemiology in Finland has been sparsely
reported, but a predominance of the CTX-M-1 group
(including blaCTX-M-15) is found (15, 16).
In other parts of Europe, accumulation of different
genotypes is found. In Spain, there is a high level of
blaCTX-M-14 and blaCTX-M-9, and in Poland as well as
several other eastern European countries blaCTX-M-3 has
been reported as frequent (17, 18).
In the African and Australian continents, blaCTX-M-15
is dominating (19). In Canada, blaCTX-M-15 is also the
most frequent and increasingly so in the United States of
America, where blaSHV-phenotypes used to be the most
encountered (20). Differences are seen between Asian
countries. In Japan, the CTX-M-9 phylogroup is largely
dominating (21) and also in China blaCTX-M-14 is more
commonly reported (22). In India, blaCTX-M-15 is almost
exclusively found (23). South America stands out with a
wide distribution of the CTX-M 2 phylogroup. Also the
CTX-M-8 phylogroup is found in South Americawhich is
rare on other continents (12, 19).
Dissemination of ESBLs
Transmission of genes encoding ESBL enzymes can occur
either by emerging bacterial clones or by horizontal gene
transfer. In the latter case, plasmids containing resistance
genes are spread between bacteria of the same and/or
different species.
The gut flora is an ideal reservoir for antibiotic
resistance genes, where kilograms of bacteria of different
species can interact, most often without causing disease
and hence to much interference with the immune system.
When antibiotics are used resistant strains gain a selec-
tive advantage and are accumulated. This increases the
probability for genes important for survival to be further
disseminated. Plasmids can contain resistance genes to
several classes of antibiotics (24). This can explain the
multiresistance often found amongst ESBL-producing
bacteria.
Clonal expansion
Clonal expansion refers to a particular bacterial cell line
multiplying and disseminating in a community or causing
an outbreak, for example, in a hospital. Rapid detection
of clonal expansions is important in order to be able to
stop or diminish the source of dissemination. Hence,
effective molecular epidemiological strain typing tools
are crucial.
An example of clonal expansion is the E. coli sequence
type 131 (ST131) that is found globally (25). ST131 is highly
associated to blaCTX-M-15 (25). In the Nordic countries,
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(13, 14, 26). However, ST131 is also found in non-ESBL E.
coli,suggestingthatST131isadominantE.colitypethathas
acquired ESBLs which may have contributed to the success-
ful dissemination of these resistance genes (25). Successful
STs of K. pneumoniae are also described. An example is the
STs of clonal complex 11 (CC11) which havebeen associated
to CTX-M dissemination (4, 27).
Outbreaks caused by EPE have occurred in the Nordic
countries. The largest ones occurred in Uppsala, Sweden
and Stavanger, Norway. The Uppsala outbreak, in 2005,
was due to a blaCTX-M-15 producing K. pneumoniae that
was spread over several ward departments of the
University Hospital. In total, 64 patients were affected
(28). Another large outbreak of blaCTX-M-15 producing K.
pneumoniae occurred in a neonatal ward department of
Stavanger University Hospital in 20082009. Fifty-eight
infants were infected, probably for receiving contami-
nated breast milk (29).
Although ST131 represent a large fraction of the
ESBL-producing E. coli population, still  50% of
Swedish isolates are genetically unrelated isolates. This
indicates that horizontal gene transfer is a major route
for disseminating ESBLs and that these resistance genes
have a remarkable ability to enter E. coli of many
different back-bones (7).
Horizontal dissemination
Plasmids are double-stranded extra-chromosomal DNA
that replicate independently of the chromosome in the
bacterialcellhostingit.Plasmidsarehighlydiverseandthe
plasmid genome is often scattered with mobile genetic
elements that can move genes around within the plasmid
aswell as between chromosome and plasmid(s). Examples
of mobile genetic elements found on plasmids are IS-
elements, transposons, integrons and insertion sequence
common regions (ISCR), of which the latter is associated
to ESBL genes. Plasmids have developed ways to secure
their persistence in the bacterial cell. One example is through
toxinantitoxin systems that act by eliminating cells that
havelosttheplasmidaftercelldivision(24).Figure1pictures
a schematic illustration of plasmid conjugation which is a
common route for plasmid dissemination.
Plasmids can be classified according to incompatibility
(Inc) groups, which are based on the principle that
plasmids with the same replicon cannot be propagated
stably in the same cell (30). The explanation for this is
that similar plasmids compete over common cellular
functions involved in, for example, plasmid replication
control (31).
A replicon is a highly conserved part of the plasmid
where genes encoding replication initiation, control, copy
number, etc. are situated (illustrated as the plasmid core
genome in Figure 2). Nowadays incompatibility grouping
have been replaced by replicon typing which is simpler
experimentally and also allows for a subdivision of some
of the Inc groups. One example is the IncF1 plasmids that
include repFIA, FIB and FIC of which repFIA and FIB
plasmids are commonly found to harbor ESBL genes.
The host range of plasmids is largely determined by
the Inc type. IncF plasmids are large narrow host range
plasmids with low copy number. They are the most
common Inc type associated to CTX-M ESBLs. IncA/C
plasmids, found associated to ESBLM and ESBLCARBA,
are contrarily broad host range plasmids that are found in
a wide variety of bacterial species. Some Inc groups are
considered as endemic resistance plasmids in Entero-
bacteriaceae. These are IncF, IncA/C, IncL/M, IncN and
IncI (32).
Among fully sequenced E. coli plasmids harboring
blaCTX-M-genes in GenBank, the following plasmid
families are found: IncF, IncN, IncN2, IncI1, IncHI2,
IncL/M, IncA/C, IncK, IncX4, IncU and RCR (33).
Fig. 1. Illustration of bacterial conjugation.
Fig. 2. A schematic illustration of a plasmid.
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high. In Norwegian and Swedish, ESBL-producing E.
coli IncF plasmids are almost exclusively found (13, 34).
Subtyping by replicon sequence typing RST) however
shows a great variability within F-plasmids, and it is not
possible to link a specific IncF-plasmid to the successful
dissemination of blaCTX-Ms (35). IncF plasmids are found
also in antibiotic-sensitive Enterobacteriaceae suggesting
that the ESBL genes have entered an already well-
established plasmid type which has been beneficial for
their dissemination (36).
Epidemiology of EPE
The Nordic countries are considered low prevalence
countries, but the EPE numbers are increasing fast. In
Sweden, national surveillance has been performed since
2007 when ESBLs were included in the communicable
disease act. The number of cases have increased from
2099 in 2007 (FebDec) to 8131 in 2013.
Several studies pictures the local frequency in different
parts of Sweden; Helldal et al. described the prevalence of
ESBL-producing E. coli in South Western Sweden during
20042008 with a higher increase in nosocomially ac-
quired isolates in comparison to community-acquired,
0.22.5% and 0.21.6%, respectively (37). A study from
the county of O ¨ stergo ¨tland indicated an increased pre-
valence of EPE from 2002 to 2007, yet the numbers were
very low (B1%) (38). An investigation of the fecal carriage
of ESBL-producing bacteria in both Primary Health Care
Units and University Hospital setting in southern Sweden
was conducted in 20082010. The only species found was
E. coli, and the authors described the prevalence as higher
than expected in both groups, 2.13% and 1.86.8%,
respectively (39). A recent study from Uppsala investi-
gated the prevalence of EPE in healthy preschool children
compared to patients in the same age group. The authors
found a carrier rate of 2.9% in healthy children compared
to 8.4% in patients of the corresponding age group (40). In
Helsinki, Finland, the annual incidence rate of EPE has
gone from 0.5/100 000 inhabitants in the year 2000 to 69/
100000in2004(15).In Denmark,therate ofinvasiveEPE
has increased from 2.5% in 2006 to 6.2% in 2009 (41). The
annual report of antibiotic resistance isolates in Norway,
Norm/Norm-Vet, published in 2012 states that EPE is
increasing steadily, and the number of EPE in blood
cultures has increased from 3.3% in 2011 to 5.5% in 2012
(42).
In Europe, the prevalence of bacteria resistant to
extended spectrum cephalosporins differs a lot between
countries. They are less frequent in the north and more
common in the southern and eastern parts of Europe. The
European network of national surveillance systems of
antimicrobial resistance summarizes the levels of invasive
infections caused by resistant bacteria in the European
countries in a yearly report available on the ECDC
homepage: http://ecdc.europa.eu/. The results are also
illustratedoncolor-codedmaps.InFig.3,levelsofinvasive
E. coli infections resistant to third-generation cephalos-
porinsareillustratedovertime.However,onemustkeepin
mindthattheresultsarebiasedbydifferencesinreporting,
national monitoring and sampling.
Looking at countries outside Europe the ESBL
prevalence also varies a lot. A recent study from the
USA presents results from the SENTRY surveillance
program including 26 hospitals from 20 states. The
resistance levels to cephalosporins and/or aztreonam in
invasive Enterobacteriaceae was 6.4% (43).
A Canadian study reported ESBL-production in
almost 5% of the E. coli population  numbers similar
to northern Europe (44).
The level of resistant bacteria is truly troublesome in
other parts of the world. In Thailand, carriage of ESBL-
producing bacteria, in as high numbers as 52% of healthy
volunteers, has been reported (45). In India, the reports
are also alarming with high numbers seen among
patients. A study from two hospitals in Ujjain, India,
collected consecutive isolates from incoming patients
with abscesses, UTI, BSI, etc. and found ESBL produc-
tion in 69% of E. coli (46).
One factor contributing to the low EPE numbers in the
Nordic countries is the restricted antibiotic treatment
policies. Antibiotics can only be purchased through
prescriptions. But despite the strict antibiotic policy and
decreasing antibiotic consumption, EPE is still increasing
(47). It has been shown that one entry of EPE to low
prevalence countries is through traveling to countries
with higher prevalence. In 2010, Ta ¨ngden et al. studied
the acquisition of resistance genes as a result of travel
outside northern Europe. Healthy travelers voluntarily
participated in taking fecal samples before and after
travel. The study resulted in 24% returning as new
carriers of EPE after travel (48). Patients admitted to
an Infectious Disease department in Aarhus, Denmark,
who had been abroad within 3 months were identified
and subjected to screening for multidrug resistant bacter-
ia. EPE colonization was found in 12.5% of which  80%
had been abroad for longer than 2 weeks (49).
Many countries outside Scandinavia (e.g. the member
states of the European Union) also have antibiotic
prescribing policies where prescription is required for
antibiotics to be purchased. Other countries lack such
regulations and the implementation of the policies differs
between countries. Acquisition of antibiotics ‘over the
counter’ in pharmacies or equivalents still occurs in many
places. There are also differences in prescribing tradition
and culture between countries. The climate affects the
frequency of infections and also the rate of dissemination.
Economical status, household conditions and population
density also clearly play a role.
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impact on dissemination of bacteria (5052). Differences
in infection control routines are substantial between
different countries, also between European countries.
Furthermore, the microbiological diagnostic traditions
and setup of surveillance programs differ. If awareness of
the regional situation is low, preventive measures will also
be. More and more studies show that there is dissemina-
tion of bacteria between food, animal (both food-
production animals and pets) and humans (5356).
Consequently antibiotic usage and inadequate infection
control in veterinary medicine, fish farming, irrigation,
etc. also contribute to the increased spread of antibiotic
resistance.
Fig. 3. Maps generated by EARS-Net illustrating the proportion of invasive E. coli isolates resistant or intermediately resistant to
third-generation cephalosporins from reporting countries in a) 2001 and b) 2012.
Figure 3 is reprinted with permission from ECDC. Source: ECDC/EARS-Net 2001 and 2012.
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Little is known about the persistence of ESBL-producing
bacteria in patients. This is mainly due to difficulties in
studying persistence. Fecal cultures represent a snapshot
of the flora at the time of study, and low numbers of
bacteria can be difficult to detect. It has been shown that
a person can present several negative samples and then
later on still come up with a positive one (57). Another
difficulty is that negative samples prior to colonization or
confirmed infection seldom exist.
There are however some studies on the persistence of
EPE. Most are conducted after detecting nosocomial
outbreaks. One example is Lo ¨hr et al. who have followed
children and their family members for 3 years after an
outbreak in the neonatal intensive care unit in Stavanger,
Norway. The authors observed carrier length of up to
2 years in some of the children (58). Persistence in
neonates is proposed to be longer than in older children
and adults since they have not yet established a naturally
protective microbial flora. They also have an undeve-
loped immune system and are more often treated with
antibiotics (58).
Alsterlund et al. studied EPE fecal colonization after a
hospital outbreak in southern Sweden and found some
individuals to still be colonized after 5 years (57).
Another Swedish study by Tham et al. describes persis-
tence of ESBL in 10% of patients after 3 years. The
authors detected two new ESBL-producing strain types
in one of the patients indicating transfer of the resistance
phenotype (59). An alternative interpretation would be
that this patient was infected with additional strains,
although given the low frequency of EPE in Sweden the
probability seems low. Low risk of re-colonization is
beneficial when studying colonization rates, since the
probability of finding the true colonization rate, duration
of carriage and migration of plasmids between species
increases. Titelman et al. studied persistence of EPE in 61
patients over the course of 1 year. By the end of the study
period, 43% of the patients were still colonized (60). This
study resulted in different scenarios in different patients.
Some of the patients presented EPE of different species
and molecular strain types carrying the same resistance
gene over time picturing the interaction between the
bacteria in the GIT. Colonization in other patients in the
same study, however, presented one identical strain type
with the same resistance gene over time (60). The factors
behind these differences would be highly interesting to
identify.
Dissemination and persistence of ESBL-producing
bacteria have also been studied within households. A
Spanish study reported that 16.7% of people living
together with persons with known community-acquired
infectionsalsowerecolonized(61).AnotherSpanishstudy
found fecal carriage in 27.4% of household members of
known carriers. Relatives outside the household had a
15.6% carrier rate. These numbers can be comparedwith a
control group of unrelated persons where the carrier rate
was7.4%(62).AChinesestudyinvestigatedESBLcarriage
inchildren05yearsofageadmittedtoapediatricclinicin
Hong Kong and found CTX-M producing bacteria in
43.5%. In 83% of these children, at least one of the house-
hold members was also a carrier (63). A French study
found intra-family transmission from adoptive children to
their new family members at a rate of 23% (64).
A different way of studying persistence is through
plasmid dissemination. Cottell et al. investigated a
plasmid, pCT, harboring blaCTX-M-14 (the only resistance
gene on that plasmid). They transformed the plasmid into
an E. coli strain and found that it provided little or no
additional fitness to the bacteria, but still the plasmid
persisted successfully in the absence of selective antibiotic
pressure. This suggests that persistence of the plasmid is
not always dependent on the resistance gene (65).
The studies mentioned show that ESBLs can persist in
carriers for several years. They are shared within house-
holds and disseminated in the community. More research
is however needed to understand how persistence and
dissemination can be minimized. Dissemination through
plasmids adds a second dimension to this problem, and
most probably prolongs the ability for resistance pheno-
types to persist.
Conclusions
The impact of antibiotic treatment on the dissemina-
tion and persistence of resistant bacteria cannot be
underestimated. In order to use these extremely important
drugs as rational as possible, we need to gain full under-
standing of how resistance arises and all the factors that
influence dissemination. Optimized antibiotic treatment is
in turn dependent on the development of faster diagnostic
tools in order to minimize empirical treatment.
Much research is still needed in this field. Strain and
plasmid interaction and dissemination needs further
attention in order to be fully understood. The persistence
of EPE in the healthy population is also important to
learn more about. Such knowledge would contribute to
important information regarding how to handle patients
colonized with EPE in hospitals and for how long
persistence is to be expected under different conditions.
It could also give us insight in how to optimize antibiotic
treatment to be as effective as possible for patients and
yet minimize further antibiotic resistance from arising
and disseminating.
Forantibioticstobepotentalsointhefuture,promoting
rational antibiotic use in all sectors minimizes the selective
pressure for resistant bacteria. New antibiotic agents are
also needed as well as optimizing the usage of the already
available antibiotics. New treatment options can buy us
time to address this important issue that constitutes a
major public health problem.
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